Certara Enhances Its Drug Discovery Suite with Acquisition of Chemaxon

Certara, Inc. CERT, a powerhouse in the model-informed drug development sector, has recently made strides to expand its capabilities by entering into a definitive agreement to purchase Chemaxon, one of the foremost providers of chemical informatics software for drug discovery. This acquisition promises to fuse Certara's expertise in biosimulation with Chemaxon's proficiency in molecular design, potentially giving rise to a robust predictive platform for drug discovery at an impressive scale.

Strategic Expansion for Certara

With its headquarters in Princeton, New Jersey, CERT has carved out a reputable place in the pharmaceutical industry by offering an array of software solutions and services that support drug development from early discovery to market access. The addition of Chemaxon is set to enhance Certara's portfolio by integrating advanced chemical informatics, which is expected to foster innovation and efficiency within the drug discovery process.

Benefits of the Acquisition

The synergy between CERT and Chemaxon's technological offerings implies a significant boost in predictive modeling capabilities for CERT. With a broader, more integrated toolkit at its disposal, Certara will be in a better position to support pharmaceutical companies in their mission to discover and develop new drugs with improved speed and success rates.

Furthermore, this strategic move is anticipated to bolster Certara's presence in the global market, reinforcing its position as a global leader in drug development and expanding its reach to Chemaxon's existing customer base.

Certara, Chemaxon, Acquisition